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Background: Left dominant arrhythmogenic cardiomyopathy (LDAC) is a rare condition characterised by progressive
fibrofatty replacement of the myocardium of the left ventricle (LV) in combination with ventricular arrhythmias of LV
origin.
Case presentation: A thirty-five-year-old male was referred for evaluation of recurrent sustained monomorphic
ventricular tachycardia (VT) of 200 bpm and right bundle branch block (RBBB) morphology. Cardiac magnetic resonance
imaging showed late gadolinium enhancement distributed circumferentially in the epicardial layer of the LV free wall
myocardium including the rightward portion of the interventricular septum (IVS). The clinical RBBB VT was reproduced
during the EP study. Ablation at an LV septum site with absence of abnormal electrograms and a suboptimum pacemap
rendered the VT of clinical morphology noninducible. Three other VTs, all of left bundle branch block (LBBB) pattern, were
induced by programmed electrical stimulation. The regions corresponding to abnormal electrograms were identified and
ablated at the mid-to-apical RV septum and the anteroseptal portion of the right ventricular outflow tract. No abnormalities
were found at the RV free wall including the inferolateral peritricuspid annulus region. Histological examination confirmed
the presence of abnormal fibrous and adipose tissue with myocyte reduction in endomyocardial samples taken from both
the left and right aspects of the IVS.
Conclusion: LDAC rarely manifests with sustained monomorphic ventricular tachycardia. In this case, several VTs of both
RBBB and LBBB morphology were amenable to endocardial radiofrequency catheter ablation.
Keywords: Left dominant arrhythmogenic cardiomyopathy, Ventricular tachycardia, Magnetic resonance imaging,
Endomyocardial biopsy, Catheter ablation* Correspondence: stepan.havranek@lf1.cuni.cz
12nd Department of Medicine – Department of Cardiovascular Medicine,
First Faculty of Medicine, Charles University and General University Hospital
in Prague, U Nemocnice 2, Prague 128 08, Czech Republic
Full list of author information is available at the end of the article
© 2015 Havranek et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article,
unless otherwise stated.
Havranek et al. BMC Cardiovascular Disorders  (2015) 15:18 Page 2 of 6Background
Left dominant arrhythmogenic cardiomyopathy (LDAC)
has been recently introduced as a rare condition charac-
terised by progressive fibrofatty replacement exclusive to
the myocardium of the left ventricle (LV) in combination
with ventricular arrhythmias of LV origin [1-9]. Sustained
ventricular tachycardia (VT) has been observed rarely and
catheter ablation for VT in an LDAC patient has never
been reported.
Case presentation
A thirty-five-year-old male was referred for evaluation of
recurrent hemodynamically tolerated sustained mono-
morphic ventricular tachycardia of 200 bpm, which had
right bundle branch block (RBBB) morphology with left-
ward axis deviation (Figure 1). He suffered from non-
syncopal palpitations in the past 3 months. He was in
functional class NYHA I and had no symptoms suggestive
of ischemic heart disease. His medical history was unre-
markable. There was no family history of cardiomyopathies
or sudden unexplained death. His 12-lead ECG in sinus
rhythm was clearly abnormal with borderline Q-waves in
the inferior leads, mid-QRS notching and slurring of
narrow QRS complexes (QRSd of 98 ms) in limb and
right precordial leads, respectively, and flattened biphasic
or negative T waves in the inferolateral leads (Figure 1).Figure 1 ECG in sinus rhythm, clinical ventricular tachycardia (VT #1)
electrophysiological procedure (VT #2 – #4). The pacemap for VT #1 is
asterisk in Figure 3.Echocardiography detected slight LV dilatation (end-dia-
stolic diameter of 63 mm) with mild global hypokinesia
(ejection fraction of 42%). CT coronary angiography ex-
cluded coronary artery disease. Cardiac magnetic resonance
imaging (CMR) showed late gadolinium enhancement
(LGE), which was distributed circumferentially in the epi-
cardial layer of the LV free wall myocardium (approximately
one-third of the LV wall thickness) including the rightward
portion of the interventricular septum (IVS) (Figure 2).
The LGE spread also to a small adjacent region of the
mid-anterior free wall of right ventricle (RV). Moreover,
T1-weighted and SPIR magnetic resonance sequences
visualised adipose infiltration of myocardium in the anter-
ior right IVS and an adjacent portion of the anterior RV
free wall in the zone of positive LGE. The LV was slightly
dilated (end-diastolic diameter of 62 mm, end-diastolic
volume of 287 mL) with mild global hypokinesia (ejection
fraction of 50%). There were no wall motion abnormalities
of the RV. The typical scar distribution together with ECG
abnormalities and VT of RBBB morphology suggested the
diagnosis of LDAC. Treatment with bisoprolol 2.5 mg and
trandolapril 4 mg daily was initiated.
Because of recurrent VT despite medical therapy, an
electrophysiological study, 3D electroanatomical mapping,
and ablation were indicated. The procedure was performed
under local anesthesia and mild conscious sedation withand three other induced VT morphologies during the
shown in the last column corresponding to the site marked by an
Figure 2 Distribution of late gadolinium enhancement (arrows) in short axis (left upper panel) and vertical long axis view (right upper
panel) was distributed circumferentially in the subepicardial left ventricular free wall myocardium with discrete progression to the
adjacent mid-anterior free wall of the right ventricle. Note the subendocardial involvement at the RV aspect of the interventricular septum.
Histological assessment of endomyocardial samples: from the left ventricular site of abnormal electrograms indicated by the cross in Figure 3 (left
bottom panel); from right ventricular aspect of the interventricular septum (right bottom panel). Arrows indicate abnormal fibrosis and adipose
tissue. Staining: hematoxylin-eosin. Magnified 100 times.
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cedure, clinical VT of 191 bpm and RBBB morphology
(Figure 1, VT #1) was induced by programmed LV
stimulation. This was unexpectedly poorly tolerated, so
the procedure was continued with substrate mapping in
sinus rhythm (3.5 mm irrigated-tip catheter, NaviStar
Thermocool, D-curve and CARTO 3, Biosense Webster
Inc., Diamond Bar, CA, USA). The procedure was guided
by intracardiac echocardiography (AcuNav Diagnostic
Ultrasound Catheter, Acuson – Siemens, Mountain View,
CA, USA). The LV was accessed by a transseptal approach
using a steerable sheath (Agilis, St. Jude Medical Inc., St.
Paul, MN, USA) in order to enable subsequent endomyocar-
dial biopsy. As expected, endocardial LV bipolar mapping
did not reveal low-voltage areas <1.5 mV. There were a lim-
ited number of sites with abnormal electrograms, which
were located only at the apicoseptal LV region (Figure 3).
Stimulus-to-QRS (S-QRS) delay did not exceed 20 ms in
any of them. The best, but far from optimum, pacemap
(Figure 1) for the clinical VT was achieved in the mid-
inferior LV septum where the morphology of bipolar elec-
trograms was fairly normal. Despite this finding, RF energy
(Stockert EP Shuttle, Biosense Webster Inc., Diamond Bar,
CA, USA; setting: 30 W, <40°C, 30 ml/min) was delivered
at this site and its close vicinity. After the initial ablation,
we were unable to re-induce the VT of clinical morphology.
However, three other non-clinical VTs (of 206, 125 and220 bpm), all of left bundle branch block (LBBB) pattern,
were observed (Figure 1, VT #2 - #4). They were indu-
cible by programmed stimulation from the RV/LV or by
catheter manipulation and were either non-sustained or
non-tolerated. The pacemapping for VT morphology #2
and #3 suggested an exit site at the mid-to-apical RV
septum. VT morphology #4 had an inferior axis and its
exit site was located at the anteroseptal portion of the
right ventricular outflow tract (RVOT). Electroanatomical
mapping of the RV identified dispersed regions of abnor-
mal electrograms, predominantly at the septum and the
anterior/septum portions of the RVOT, while the RV
free wall including the inferolateral peritricuspid annulus
region was generally not affected. Maximum scar involve-
ment was found at the RV aspect of the IVS, where sites
with discrete late potentials and slow conduction zones
(maximum S-QRS of 50 ms) were identified (Figure 3).
Substrate-based ablation was performed rather extensively
at the RV aspect of the midseptum from the inferior to
middle segments up to the proximity of right bundle
branch (contralateral to the exit of clinical VT #1 and
close to the suspected exits of VT #2 and #3) as well as at
the anterior portion of the RVOT (site of origin of VT #4).
An endomyocardial biopsy was performed prior to abla-
tion, with an attempt to guide the catheter bioptome (7-F/
104 cm biopsy forceps, Cordis, Bridgewater, NJ, USA) into
affected regions according to electroanatomical mapping.
Figure 3 The bipolar voltage map of both ventricles in sinus rhythm. An atypical range (2–4 mV) for color-coding was used to highlight the
areas of subtle reduction of bipolar voltages. The cross denotes the left ventricular apicoseptal region of abnormal electrograms where the endomyocardial
biopsy was taken. The arrow indicates the site with a maximum stimulus-to-QRS interval at the right-sided interventricular septum. The asterisk shows the
site of the pacemap for the clinical tachycardia at the left-sided interventricular septum site with normal electrograms.
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normal fibrous and adipose tissue with myocyte reduction
in endomyocardial samples taken from both left and right
aspects of the IVS (Figure 2). Mutation screening for
desmosomal genes was not performed.
A cardioverter-defibrillator (ICD) was implanted and the
patient was discharged on the same dosage of bisoprolol
and trandolapril medication. No class I or III antiarrhythmic
drugs were given. During the 18-month follow-up, the pa-
tient experienced only a single episode of monomorphic
VT (243 bpm) when bisoprolol medication was discontin-
ued by mistake. LV dilatation and mild dysfunction
remained stable at regular check-ups.
Discussion
The phenotypic spectrum of arrhythmogenic cardiomy-
opathy includes either left dominant, right dominant or
bi-ventricular variant. Isolated left and right ventricular
abnormalities are at two extremes of the clinical mani-
festation of the disease [8]. There were no specific ECG
abnormalities in the right precordial leads in our patient.
The RV was not dilated and had normal kinetics. Typical
regions involved in classic arrhythmogenic right ventricular
cardiomyopathy (ARVC) (e.g. inferolateral peri-tricuspid
area) were free of fibrofatty replacement according to both
LGE CMR and electroanatomical mapping. The diagnosis
of LDAC in this case was based on recently established
clinical features of the disease [8]: ventricular arrhythmiaof LV origin, repolarization abnormalities in inferolateral
leads, mild LV dilatation with systolic dysfunction, and
myocardial fibrofatty replacement assessed by LGE on
CMR and confirmed by endomyocardial biopsy.
The designation as a purely LV entity might be ques-
tioned because a small region of fibrofatty replacement
was present at the mid-anterior portion of the RV free
wall, as assessed by LGE CMR. An additional region of
abnormal electrograms was present at the anterior
RVOT by electroanatomical mapping (not revealed by
CMR), complemented by the observation that inducible
VT #4 exited from this site. This is still compatible with
LDAC because LV involvement including IVS clearly
dominated and subtle RV regional abnormalities or the
presence of additional arrhythmogenic substrate in RV
has been observed in the majority of LDAC patients [8].
Although the presence of ventricular arrhythmias is an
essential component of the clinical picture of LDAC, sus-
tained monomorphic VT has been reported rarely. Be-
sides the cases diagnosed post-mortem, the predominant
arrhythmias were frequent ventricular premature beats or
non-sustained VT of LV origin [8]. Sustained VT of RBBB
morphology has been described only in a minority of pa-
tients: in 1 of 42 patients in Sen-Chowdry’s cohort [8], in 3
of 7 carriers of a dominant desmoplakin mutation in single
family [5] and in 3 more solitary case reports [3,10,11]. To
the best of our knowledge, catheter ablation has never
been performed for VT in an LDAC patient.
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LDAC may be indicated in patients with recurrent VT
despite therapy with antiarrhythmic drugs. In this case
we preferred non-pharmacological treatment because of
the considerable burden of arrhythmia, in order to pre-
vent frequent ICD therapy and to avoid long-term med-
ical therapy, which may be ineffective and/or associated
with adverse effects.
Because of the non-transmural and rather homogeneous
distribution of pathological tissue, electroanatomical map-
ping (both bipolar and unipolar) showed voltages almost
invariably within the normal arbitrary range and thus was
of little help. For this reason pre-procedural CMR was ex-
tremely valuable for tailoring the ablation strategy. It dem-
onstrated from the very beginning that the clinical VT
could only be effectively targeted by endocardial ablation
from the RV aspect of IVS - the only site where the poten-
tial substrate was localized close to the endocardial sur-
face. Any other LV targets would require an epicardial
approach. Fortunately, VT #1 - #3 originated at the IVS. It
is likely that the clinical VT (VT #1) originated from the
RV subendocardium at the IVS with a preferential leftward
exit, which could explain the RBBB morphology. Initial
ablation at the LV aspect of the IVS probably modified the
route of propagation. This explains why subsequent VT #2
and #3 had LBBB morphology. It is not known whether the
initial LV ablation had any other impact besides changing
the exit route.
Indeed, there was a preponderance of mappable ar-
rhythmogenic substrate at the RV aspect of the IVS, al-
though in sinus rhythm the abnormal electrograms were
considerably masked by the fast activation of the septum
from both sides via the intact His-Purkinje system con-
duction. Pacing from the LV would probably be helpful
maneuver to reveal pathological electrograms or late po-
tentials at the right side of the IVS, but this was not
done in the present case. Ablation at the RV aspect of
the IVS was performed rather extensively to target not
only the critical zones of inducible VTs but also to
homogenize the scar in order to prevent other VTs that
did not manifest during the procedure.
Although the patient presented with VT of RBBB
morphology, this case also suggests that, at least in theory,
LDAC may manifest by ventricular arrhythmias of LBBB
morphology alone. This might be taken into account when
the clinical criteria of LDAC are refined in the future.
Endomyocardial biopsy guided by electroanatomical
mapping confirmed the presence of fibrous and adipose
tissue in samples obtained from both aspects of the IVS.
Positive sampling from the right-sided IVS, fully affected
by the pathological process, was expected in our case.
The biopsy from the LV endomyocardium, without
macroscopic signs of pathology by LGE CMR, was taken
from the apicoseptal region of LV, which was the onlysite with borderline abnormal electrograms. Such an ap-
proach could possibly increase the diagnostic yield, as
already reported [12].
Because of structural heart disease that manifested by
malignant ventricular arrhythmia and the existence of
large-scale, potentially arrhythmogenic substrate, which
could not be safely eliminated by catheter ablation, and be-
cause of the progressive nature of disease, the cardioverter-
defibrillator was implanted for secondary prevention of
sudden cardiac death. Despite the fact that single episode of
VT was documented during the follow-up, it is likely that
catheter ablation prevented frequent VT recurrences.
Conclusion
Left dominant arrhythmogenic cardiomyopathy is an in-
frequent structural heart disease, which rarely manifests
with sustained monomorphic ventricular tachycardia. In
this case, extensive circumferential LV involvement by
fibrofatty replacement was distributed epicardially at the
LV free wall and subendocardially at the RV aspect of
the interventricular septum. Several VTs of both RBBB
and LBBB morphology were amenable to endocardial ra-
diofrequency catheter ablation.
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